SCHEMBL16807284

SCHEMBL16807284

Cc1cccc(C(C(=O)c2ccccc2)c2ccccc2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.69
TDP1 Q9NUW8 1/20 0.69
ACP3 P15309 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
PTPN1 P18031 1/20 0.48
CES2 O00748 1/20 0.47
LMNA P02545 1/20 0.47
CES1 P23141 1/20 0.47
POLB P06746 3/20 0.46
PARP1 P09874 1/20 0.46
GPR139 Q6DWJ6 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
MGAM O43451 1/20 0.44
GAA P10253 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
KCNK3 O14649 1/20 0.44
KCNK9 Q9NPC2 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16807273 0.95 L3MBTL1 (0.62) L3MBTL1TDP1ACP3SMN1; SMN2PTPN1
SCHEMBL16807276 0.89 L3MBTL1 (0.54) L3MBTL1TDP1ACP3SMN1; SMN2CES2
SCHEMBL16781991 0.88 L3MBTL1 (0.71) L3MBTL1TDP1SMN1; SMN2PTPN1CES2
SCHEMBL2928039 0.84 L3MBTL1 (0.77) L3MBTL1TDP1SMN1; SMN2PTPN1CES2
SCHEMBL7076176 0.84 ACP3 (0.54) L3MBTL1TDP1ACP3SMN1; SMN2POLB
SCHEMBL2927912 0.83 L3MBTL1 (1.00) L3MBTL1TDP1PTPN1CES2LMNA
SCHEMBL11587930 0.83 CES2 (0.67) L3MBTL1TDP1ACP3SMN1; SMN2CES2
SCHEMBL12071036 0.83 MAPT (0.54) L3MBTL1TDP1ACP3SMN1; SMN2CES2
SCHEMBL22917247 0.82 ACP3 (0.53) L3MBTL1TDP1ACP3SMN1; SMN2LMNA
SCHEMBL16781997 0.82 L3MBTL1 (0.73) L3MBTL1TDP1SMN1; SMN2PTPN1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656947-B2 Process for creating carbon-carbon bonds using carbonyl compounds CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) 2017-05-23 US disclosed
US-9656947-B2 Process for creating carbon-carbon bonds using carbonyl compounds CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) 2017-05-23 US disclosed
EP-2858966-B1 PROCESS FOR CREATING CARBON-CARBON BONDS USING CARBONYL COMPOUNDS CENTRE NAT RECH SCIENT (FR) 2016-08-10 EP disclosed
US-20150166464-A1 PROCESS FOR CREATING CARBON-CARBON BONDS USING CARBONYL COMPOUNDS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. R.S.) (FR) 2015-06-18 US disclosed
US-20150166464-A1 PROCESS FOR CREATING CARBON-CARBON BONDS USING CARBONYL COMPOUNDS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. R.S.) (FR) 2015-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166464-A1 PROCESS FOR CREATING CARBON-CARBON BONDS USING CARBONYL COMPOUNDS CBR3, CBR1, CYP4F3 L3MBTL1 4386/4885TDP1 4876/4885ACP3 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.